Prothena Corp. plc (PRTA), a late-stage clinical biotechnology company, is on the verge of a potentially transformative year ahead, as it prepares for key data readouts over the next 12 months.
The company has a diverse pipeline of novel investigational therapies derived from its Protein Dysregulation Platform, which have the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. It has wholly owned programs as well as programs being developed in collaborations with Roche, Bristol Myers Squibb, and Novo Nordisk.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com